Cross-Sector entity
Mineralys Therapeutics is most often covered alongside EHang, which appears in 4 of these 7 stories. earnings accounts for 3 of the 7 tracked stories, while 3 other categories carry the remainder. 0% of these stories carry negative sentiment. We currently track 7 Cross-Sector stories that mention Mineralys Therapeutics, published between March 12, 2026 and March 13, 2026.
7 verified stories tracked
Last mentioned: Mar 13, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 57 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Mineralys Therapeutics is most often covered alongside EHang, which appears in 4 of these 7 stories. earnings accounts for 3 of the 7 tracked stories, while 3 other categories carry the remainder. 0% of these stories carry negative sentiment. We currently track 7 Cross-Sector stories that mention Mineralys Therapeutics, published between March 12, 2026 and March 13, 2026. The tracked stories average 9.4 original sources each.
Computed from the 7 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Mineralys Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Lorundrostat PDUFA Date
Target date for FDA decision on Mineralys' lead product candidate.
Nektar Phase 3 Launch
Nektar plans first patient randomization for its Atopic Dermatitis program.
Q4 2025 Earnings
Both Mineralys and Vuzix report year-end financial results and 2026 guidance.
Mineralys NDA Acceptance
FDA accepts Mineralys' NDA for lorundrostat for uncontrolled hypertension.
FDA NDA Acceptance
FDA formally accepts Mineralys Therapeutics' application for Lorundrostat.
PDUFA Goal Date
Expected timeframe for the FDA's final decision on Lorundrostat commercialization.
EHang Record Deliveries
EHang closes Q4 with 100 eVTOL units delivered and first GAAP profit.
HeartBeam FDA Clearance
HeartBeam secures 510(k) clearance for 12-lead ECG synthesis software.
The Q4 2025 earnings cycle reveals a significant acceleration in AI-driven operational efficiency and product innovation across healthcare, aviation, and enterprise services. Key developments include CareCloud's successful automation of patient scheduling and HeartBeam's FDA-cleared AI diagnostic software, signaling a shift from experimental AI to core revenue-generating applications.
CareCloud achieved its first profitable year since its 2014 IPO, driven by its AI Center of Excellence and strategic acquisitions. Meanwhile, HeartBeam and Vuzix are pivoting toward high-margin software and engineering services, signaling a broader trend of hardware-to-SaaS transitions.
The Q4 2025 earnings cycle marks a pivot toward commercial maturity for high-growth ventures, highlighted by Mineralys Therapeutics' FDA filing and EHang's first GAAP-profitable quarter. These results signal a de-risking phase for investors as pre-revenue startups transition into regulated, revenue-generating entities.
EHang (EH) achieved its first quarterly GAAP profit on record eVTOL deliveries, signaling a commercial inflection point for Advanced Air Mobility. Simultaneously, Vuzix (VUZI) reported a 76% revenue surge in smart glasses and waveguide technology, underscoring robust demand for dual-use augmented reality systems.
Mineralys Therapeutics secured a major regulatory win with FDA acceptance of its Lorundrostat NDA, while Vuzix continues to navigate the transition from pilot programs to enterprise-scale AR deployments.
Mineralys Therapeutics (MLYS) reported a narrower-than-expected Q4 2025 loss and confirmed the FDA's acceptance of its New Drug Application for lorundrostat. The company is now pivoting toward commercial readiness for its lead hypertension candidate while maintaining a robust clinical pipeline in chronic kidney disease.
Mineralys (MLYS) and Vuzix (VUZI) reported Q4 2025 results, highlighting divergent but critical paths in healthcare innovation: the clinical validation of next-generation hypertension therapies and the operational scaling of augmented reality in surgical settings. While Mineralys focuses on pivotal trial readouts for lorundrostat, Vuzix is navigating a transition toward OEM and high-margin medical software solutions.
